JP2017513864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513864A5 JP2017513864A5 JP2016563113A JP2016563113A JP2017513864A5 JP 2017513864 A5 JP2017513864 A5 JP 2017513864A5 JP 2016563113 A JP2016563113 A JP 2016563113A JP 2016563113 A JP2016563113 A JP 2016563113A JP 2017513864 A5 JP2017513864 A5 JP 2017513864A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- channel activator
- item
- subject
- ion channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 214
- 239000012190 activator Substances 0.000 claims description 93
- 102000004310 Ion Channels Human genes 0.000 claims description 52
- 108090000862 Ion Channels Proteins 0.000 claims description 52
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
- 230000004118 muscle contraction Effects 0.000 claims description 31
- 208000005392 Spasm Diseases 0.000 claims description 28
- -1 linktas Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 208000007101 Muscle Cramp Diseases 0.000 claims description 16
- 108010036769 TRPA1 Cation Channel Proteins 0.000 claims description 15
- 102000012253 TRPA1 Cation Channel Human genes 0.000 claims description 15
- 210000003205 muscle Anatomy 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 108091006146 Channels Proteins 0.000 claims description 14
- 208000014094 Dystonic disease Diseases 0.000 claims description 14
- 208000010118 dystonia Diseases 0.000 claims description 13
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 claims description 12
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 claims description 12
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 12
- UBJVUCKUDDKUJF-UHFFFAOYSA-N Diallyl sulfide Chemical compound C=CCSCC=C UBJVUCKUDDKUJF-UHFFFAOYSA-N 0.000 claims description 12
- 102000003566 TRPV1 Human genes 0.000 claims description 12
- 101150016206 Trpv1 gene Proteins 0.000 claims description 12
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical group C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims description 12
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 claims description 12
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 claims description 10
- PSKIOIDCXFHNJA-UHFFFAOYSA-N Sanshool Natural products CC=CC=CC=CCCC=CC=CC(=O)NC(C)C PSKIOIDCXFHNJA-UHFFFAOYSA-N 0.000 claims description 10
- SBXYHCVXUCYYJT-UEOYEZOQSA-N alpha-Sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)C SBXYHCVXUCYYJT-UEOYEZOQSA-N 0.000 claims description 10
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 10
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 10
- 235000002780 gingerol Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 6
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 6
- LZPKWQOLOCLSBO-UHFFFAOYSA-N 6-(trifluoromethyl)-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CC=C2CC(=O)NC2=C1 LZPKWQOLOCLSBO-UHFFFAOYSA-N 0.000 claims description 6
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 6
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 6
- 239000005770 Eugenol Substances 0.000 claims description 6
- 208000026072 Motor neurone disease Diseases 0.000 claims description 6
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 6
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 6
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 6
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000010081 allicin Nutrition 0.000 claims description 6
- 235000016720 allyl isothiocyanate Nutrition 0.000 claims description 6
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 6
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 6
- 229960004242 dronabinol Drugs 0.000 claims description 6
- 229960002217 eugenol Drugs 0.000 claims description 6
- 210000001087 myotubule Anatomy 0.000 claims description 6
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 claims description 6
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 208000013465 muscle pain Diseases 0.000 claims description 5
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000004530 micro-emulsion Substances 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 235000015111 chews Nutrition 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 208000000412 Avitaminosis Diseases 0.000 claims description 2
- 206010006542 Bulbar palsy Diseases 0.000 claims description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 2
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044074 Torticollis Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010005159 blepharospasm Diseases 0.000 claims description 2
- 230000000744 blepharospasm Effects 0.000 claims description 2
- 201000006997 bulbospinal polio Diseases 0.000 claims description 2
- 206010008129 cerebral palsy Diseases 0.000 claims description 2
- 201000002866 cervical dystonia Diseases 0.000 claims description 2
- 201000002904 focal dystonia Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 210000004237 neck muscle Anatomy 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 claims description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- ZICNYIDDNJYKCP-SOFGYWHQSA-N capsiate Chemical compound COC1=CC(COC(=O)CCCC\C=C\C(C)C)=CC=C1O ZICNYIDDNJYKCP-SOFGYWHQSA-N 0.000 description 6
- RBCYRZPENADQGZ-UHFFFAOYSA-N dihydrocapsaicin Natural products COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- NBXZJPXDDBBXBL-KHPPLWFESA-N (Z)-N-[2-(4,5-dihydroxy-5-methylcyclohexa-1,3-dien-1-yl)ethyl]octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(C)(O)C1 NBXZJPXDDBBXBL-KHPPLWFESA-N 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 4
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 4
- KAWOEDMUUFFXAM-UHFFFAOYSA-N CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 Polymers CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 KAWOEDMUUFFXAM-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N Dopamine Natural products NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 4
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 4
- AKDLSISGGARWFP-UHFFFAOYSA-N Homodihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCCC(C)C)=CC=C1O AKDLSISGGARWFP-UHFFFAOYSA-N 0.000 description 4
- QQBPLXNESPTPNU-KTKRTIGZSA-N N-oleoyldopamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(O)=C1 QQBPLXNESPTPNU-KTKRTIGZSA-N 0.000 description 4
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- AZJUJOFIHHNCSV-KCQAQPDRSA-N Polygodial Polymers C[C@@]1([C@H](C(C=O)=CC2)C=O)[C@@H]2C(C)(C)CCC1 AZJUJOFIHHNCSV-KCQAQPDRSA-N 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 235000010358 acesulfame potassium Nutrition 0.000 description 4
- 239000000619 acesulfame-K Substances 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 4
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 229940109275 cyclamate Drugs 0.000 description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 4
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 4
- 229960004369 flufenamic acid Drugs 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 235000011087 fumaric acid Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 4
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 4
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- FPGPDEPMWUWLOV-UHFFFAOYSA-N polygodial Natural products CC1(C)CCCC2(C)C(C=O)C(=CC(O)C12)C=O FPGPDEPMWUWLOV-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- BXBVPYSHEOQGHP-UHFFFAOYSA-N Nordihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCC(C)C)=CC=C1O BXBVPYSHEOQGHP-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- 239000004204 candelilla wax Substances 0.000 description 2
- 235000013868 candelilla wax Nutrition 0.000 description 2
- 229940073532 candelilla wax Drugs 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 208000024980 claudication Diseases 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- MLJGZARGNROKAC-VQHVLOKHSA-N homocapsaicin Chemical compound CCC(C)\C=C\CCCCC(=O)NCC1=CC=C(O)C(OC)=C1 MLJGZARGNROKAC-VQHVLOKHSA-N 0.000 description 2
- JKIHLSTUOQHAFF-UHFFFAOYSA-N homocapsaicin Natural products COC1=CC(CNC(=O)CCCCCC=CC(C)C)=CC=C1O JKIHLSTUOQHAFF-UHFFFAOYSA-N 0.000 description 2
- JZNZUOZRIWOBGG-UHFFFAOYSA-N homocapsaicin-II Natural products COC1=CC(CNC(=O)CCCCC=CCC(C)C)=CC=C1O JZNZUOZRIWOBGG-UHFFFAOYSA-N 0.000 description 2
- GOBFKCLUUUDTQE-UHFFFAOYSA-N homodihydrocapsaicin-II Natural products CCC(C)CCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 GOBFKCLUUUDTQE-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000012169 petroleum derived wax Substances 0.000 description 2
- 235000019381 petroleum wax Nutrition 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 2
- 229940073454 resiniferatoxin Drugs 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- UTNZMGHHFHHIAY-FNORWQNLSA-N Norcapsaicin Chemical compound COC1=CC(CNC(=O)CCC\C=C\C(C)C)=CC=C1O UTNZMGHHFHHIAY-FNORWQNLSA-N 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- UTNZMGHHFHHIAY-UHFFFAOYSA-N norcapsaicin Natural products COC1=CC(CNC(=O)CCCC=CC(C)C)=CC=C1O UTNZMGHHFHHIAY-UHFFFAOYSA-N 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979349P | 2014-04-14 | 2014-04-14 | |
| US61/979,349 | 2014-04-14 | ||
| US201462073131P | 2014-10-31 | 2014-10-31 | |
| US201462073258P | 2014-10-31 | 2014-10-31 | |
| US62/073,131 | 2014-10-31 | ||
| US62/073,258 | 2014-10-31 | ||
| PCT/US2015/025811 WO2015160843A1 (en) | 2014-04-14 | 2015-04-14 | Ion channel activators and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513864A JP2017513864A (ja) | 2017-06-01 |
| JP2017513864A5 true JP2017513864A5 (cg-RX-API-DMAC10.html) | 2018-06-14 |
Family
ID=54324508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563113A Pending JP2017513864A (ja) | 2014-04-14 | 2015-04-14 | イオンチャネル活性化剤及び使用方法 |
Country Status (14)
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6907884B2 (en) | 2002-09-30 | 2005-06-21 | Depay Acromed, Inc. | Method of straddling an intraosseous nerve |
| US7258690B2 (en) | 2003-03-28 | 2007-08-21 | Relievant Medsystems, Inc. | Windowed thermal ablation probe |
| US8361067B2 (en) | 2002-09-30 | 2013-01-29 | Relievant Medsystems, Inc. | Methods of therapeutically heating a vertebral body to treat back pain |
| US10028753B2 (en) | 2008-09-26 | 2018-07-24 | Relievant Medsystems, Inc. | Spine treatment kits |
| CA2737374C (en) | 2008-09-26 | 2017-03-28 | Relievant Medsystems, Inc. | Systems and methods for navigating an instrument through bone |
| US10390877B2 (en) | 2011-12-30 | 2019-08-27 | Relievant Medsystems, Inc. | Systems and methods for treating back pain |
| US10588691B2 (en) | 2012-09-12 | 2020-03-17 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
| KR101748053B1 (ko) | 2012-10-17 | 2017-06-15 | 메틸레이션 사이언시즈 인터내셔널 에스알엘 | S-아데노실메티오닌 및 갈산 에스테르가 포함된 조성물 |
| IL238516B (en) | 2012-11-05 | 2022-08-01 | Relievant Medsystems Inc | System and methods for creating curved pathways through bone and regulating the nerves within the bone |
| US9724151B2 (en) | 2013-08-08 | 2017-08-08 | Relievant Medsystems, Inc. | Modulating nerves within bone using bone fasteners |
| WO2016170501A1 (en) * | 2015-04-24 | 2016-10-27 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| AU2016336544A1 (en) * | 2015-10-06 | 2018-04-26 | Flex Pharma, Inc. | Methods and compositions for unwanted or abnormal muscle contractions |
| WO2017160156A1 (en) * | 2016-03-18 | 2017-09-21 | Axichem Ab | Synthetic capasaicin analogs as trpv1 agonists |
| NO341559B1 (en) * | 2016-03-18 | 2017-12-04 | Axichem Ab | Synthetic capsaicinoid derivatives and feed comprising such compounds as growth promotors |
| WO2017218697A1 (en) * | 2016-06-17 | 2017-12-21 | The Trustees Columbia University In The City Of New York | Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans |
| US11000490B2 (en) | 2016-11-02 | 2021-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
| CN106619585B (zh) * | 2016-11-24 | 2019-03-01 | 中国人民解放军第四军医大学 | 肉桂醛及其衍生物在制备防治肺纤维化的药物中的应用 |
| US10918685B2 (en) * | 2017-01-05 | 2021-02-16 | Ravi Ramamoorthy Iyer | Herbal topical composition for muscle and joint health, recovery from exertion, and for pain management |
| US11253493B2 (en) | 2017-01-23 | 2022-02-22 | Cliff-Cartwright Corporation | Compositions and methods affecting exercise performance |
| JP2020506207A (ja) * | 2017-02-09 | 2020-02-27 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 末梢動脈疾患の治療のための組成物および方法 |
| WO2019018769A1 (en) | 2017-07-20 | 2019-01-24 | Centrexion Therapeutics Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE |
| US11554104B2 (en) * | 2017-08-18 | 2023-01-17 | The Schepens Eye Research Institute, Inc. | Compositions for the treatment of dry eye and methods of use thereof |
| US12138274B2 (en) | 2018-11-08 | 2024-11-12 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases |
| CN113490745A (zh) * | 2018-12-21 | 2021-10-08 | 索伦托药业有限公司 | 神经周施用树脂毒素治疗适应不良性疼痛 |
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| JP7177738B2 (ja) * | 2019-03-26 | 2022-11-24 | サントリーホールディングス株式会社 | リナロール含有飲料 |
| WO2020241754A1 (ja) * | 2019-05-31 | 2020-12-03 | サントリーホールディングス株式会社 | ノンアルコールビールテイスト飲料 |
| CA3143042A1 (en) * | 2019-06-11 | 2020-12-17 | Pano Therapeutics, Inc. | Capsaicin and trpv1 modulator combinations and methods of use thereof |
| EP3753417A1 (en) | 2019-06-20 | 2020-12-23 | PerformaNat GmbH | Feed additive |
| US11707437B2 (en) * | 2019-07-12 | 2023-07-25 | Board Of Trustees Of Southern Illinois University | Topical formulations with resiniferatoxin nanoparticles and methods |
| AU2020346827B2 (en) | 2019-09-12 | 2026-03-12 | Relievant Medsystems, Inc. | Systems and methods for tissue modulation |
| PH12022550262A1 (en) * | 2019-09-23 | 2022-11-21 | Unilever Ip Holdings B V | Oil-in-water emulsion comprising plant protein |
| CN110664990B (zh) * | 2019-11-07 | 2021-03-16 | 江南大学 | 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用 |
| KR102303624B1 (ko) * | 2020-01-22 | 2021-09-16 | 한국식품연구원 | 머위잎 추출물을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물 |
| WO2021168463A1 (en) * | 2020-02-21 | 2021-08-26 | Douglas Thomas | Buccal and enteric delivery of fatty acids in foods and beverages |
| US20230143545A1 (en) * | 2020-03-30 | 2023-05-11 | Board Of Regents Of The University Of Nebraska | Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin |
| AU2021306313B2 (en) | 2020-07-10 | 2026-07-09 | Relievant Medsystems, Inc. | Vertebral denervation in conjunction with vertebral fusion |
| US12082876B1 (en) | 2020-09-28 | 2024-09-10 | Relievant Medsystems, Inc. | Introducer drill |
| JP7878625B2 (ja) * | 2020-11-16 | 2026-06-23 | ハウスウェルネスフーズ株式会社 | アドレノメデュリン遺伝子発現増強用組成物 |
| AU2021409967A1 (en) | 2020-12-22 | 2023-08-03 | Relievant Medsystems, Inc. | Prediction of candidates for spinal neuromodulation |
| US20240299348A1 (en) * | 2021-01-08 | 2024-09-12 | Caraway Therapeutics, Inc. | Modulators of trpml, their compositions and methods of use |
| US20240099998A1 (en) * | 2021-01-15 | 2024-03-28 | Dignify Therapeutics, Llc | Compositions and methods for inducing defecation |
| CN113243338A (zh) * | 2021-05-14 | 2021-08-13 | 福州大学 | 一种小鼠缺血性卒中模型的构建与评估方法 |
| CA3221865A1 (en) | 2021-06-07 | 2022-12-15 | Nodari RIZUN | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products |
| JP2023010677A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| US12433668B1 (en) | 2021-11-08 | 2025-10-07 | Relievant Medsystems, Inc. | Impedance stoppage mitigation during radiofrequency tissue ablation procedures |
| US20240423952A1 (en) * | 2021-11-15 | 2024-12-26 | Ibagen Pharmaceuticals, Inc. | Compositions and methods for treating congenital disorders |
| JP7825975B2 (ja) * | 2021-11-16 | 2026-03-09 | ハウスウェルネスフーズ株式会社 | アドレノメデュリン遺伝子発現増強用組成物 |
| CN119013010A (zh) * | 2021-12-16 | 2024-11-22 | 艾维尔勒斯生物公司 | 用于治疗慢性肺病的可吸入或可摄入的乳酸组合物 |
| CN115006342A (zh) * | 2022-04-14 | 2022-09-06 | 辽宁天融生物科技有限公司 | 一种抗高尿酸活性组分及其应用方法 |
| CN114869869B (zh) * | 2022-04-21 | 2023-09-19 | 北京积水潭医院 | Eugenol在预防和/或治疗骨关节炎中的应用 |
| CN115444845B (zh) * | 2022-08-05 | 2023-07-21 | 四川大学华西医院 | 一种促进伤口愈合的组合物和智能涂层材料 |
| CN115844049B (zh) * | 2022-11-21 | 2024-12-10 | 深圳市真味生物科技有限公司 | 一种不添加烟碱的薄荷烟草电子雾化液及其制备方法 |
| WO2024118705A1 (en) * | 2022-11-29 | 2024-06-06 | Neuro-Innovators, Llc | Neurorestoration compound implementing multiple neuroplasticity inducing mechanisms of action |
| JP2026500538A (ja) * | 2022-12-23 | 2026-01-07 | デブレツェン エジェテム | Ｈ２ｓ放出化合物を用いたミエロペルオキシダーゼ陽性ａｎｃａ関連血管炎の処置 |
| JP2024159343A (ja) * | 2023-04-28 | 2024-11-08 | 住友化学株式会社 | 昆虫細胞を拡大培養する方法 |
| EP4712796A2 (en) * | 2023-05-15 | 2026-03-25 | Bonafide Health, LLC | Sleep-improving compositions and methods of use |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
| WO2025024655A1 (en) * | 2023-07-25 | 2025-01-30 | Balance Lytes, Llc | Urea compositions and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09176002A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のジンゲロール含有合成抑制剤 |
| ATE285769T1 (de) * | 1998-12-04 | 2005-01-15 | Neurosearch As | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| US6592896B2 (en) * | 2001-08-06 | 2003-07-15 | The Quigley Corporation | Medicinal composition and method of using it |
| BRPI0513465B1 (pt) * | 2004-08-11 | 2015-08-11 | Intercontinental Great Brands Llc | Composições orais, artigo comestível, composições para balas e goma de mascar, métodos para preparação do referido artigo e para fornercer sensação às áreas receptoras orais |
| CN101001537B (zh) * | 2004-08-11 | 2013-12-18 | 卡夫食品全球品牌有限责任公司 | 感觉剂组合物和它的输送体系 |
| WO2007044748A2 (en) * | 2005-10-11 | 2007-04-19 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| US20080021034A1 (en) * | 2006-04-10 | 2008-01-24 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| CN102112121A (zh) * | 2008-03-11 | 2011-06-29 | 哈佛大学校长及研究员协会 | 用于治疗疼痛和瘙痒的方法、组合物和药盒 |
| US20090304827A1 (en) * | 2008-05-08 | 2009-12-10 | Kim Darrick S H L | Combinations of Ingredients Having Synergistic Anti-Inflammatory Effects |
| PL2629610T3 (pl) * | 2010-07-27 | 2018-02-28 | Flex Pharma, Inc. | Sposoby i kompozycje do zapobiegania i zmniejszania kurczy mięśni i do regeneracji po nerwowo-mięśniowym podrażnieniu i zmęczeniu po ćwiczeniach fizycznych |
| US9211274B2 (en) * | 2012-02-01 | 2015-12-15 | Warsaw Orthopedic, Inc. | TRPV1 compounds in a biodegradable polymer carrier |
| WO2013155365A1 (en) * | 2012-04-12 | 2013-10-17 | University Of Maryland | Markers for diagnosing amyotrophic lateral sclerosis |
| BR112015017176A2 (pt) * | 2013-01-18 | 2017-07-11 | Tonix Pharmaceuticals Inc | isômero isometepteno |
-
2015
- 2015-04-14 MX MX2016013486A patent/MX2016013486A/es unknown
- 2015-04-14 US US15/304,418 patent/US20170042834A1/en not_active Abandoned
- 2015-04-14 AU AU2015247815A patent/AU2015247815A1/en not_active Abandoned
- 2015-04-14 KR KR1020167031289A patent/KR20160143792A/ko not_active Withdrawn
- 2015-04-14 SG SG11201608383WA patent/SG11201608383WA/en unknown
- 2015-04-14 BR BR112016024034A patent/BR112016024034A2/pt not_active IP Right Cessation
- 2015-04-14 CA CA2945795A patent/CA2945795A1/en not_active Abandoned
- 2015-04-14 EP EP15780197.8A patent/EP3131541A4/en not_active Withdrawn
- 2015-04-14 WO PCT/US2015/025811 patent/WO2015160843A1/en not_active Ceased
- 2015-04-14 JP JP2016563113A patent/JP2017513864A/ja active Pending
- 2015-04-14 CN CN201580020008.7A patent/CN106232110A/zh active Pending
- 2015-04-14 EA EA201692060A patent/EA201692060A1/ru unknown
-
2016
- 2016-09-27 ZA ZA2016/06684A patent/ZA201606684B/en unknown
- 2016-10-13 IL IL248339A patent/IL248339A0/en unknown
-
2018
- 2018-02-28 US US15/908,070 patent/US20190038573A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190038573A1 (en) | Ion channel activators and methods of use | |
| JP7284241B2 (ja) | 即効性の植物由来医薬化合物及び栄養補給剤 | |
| JP7066210B2 (ja) | 即効性の植物由来医薬化合物及び栄養補給剤 | |
| MX2018001487A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6 y la composición farmacéutica que comprende los mismos. | |
| MX2018004447A (es) | Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| JP7281815B2 (ja) | 医薬化合物及び栄養補給剤 | |
| WO2015160842A1 (en) | Methods and formulatiions of capsaicinoids and capsinoids | |
| JP2014114305A5 (cg-RX-API-DMAC10.html) | ||
| JP2024009945A (ja) | 改善されたバイオアベイラビリティーを有するハーブ組成物 | |
| JP2014501287A5 (cg-RX-API-DMAC10.html) | ||
| JP2018533618A5 (cg-RX-API-DMAC10.html) | ||
| WO2003065989A3 (en) | (oxime)carbamoyl fatty acid amide hydrolase inhibitors | |
| HRP20200394T1 (hr) | Smjesa masnih kiselina (gmk, grupa masnih kiselina) za primjenu u liječenju inflamatornih patologija | |
| JP2018533556A (ja) | 望ましくないまたは異常な筋収縮のための方法および組成物 | |
| CN105120900A (zh) | 用于治疗慢性炎症和炎性疾病的组合物及方法 | |
| CL2012001501A1 (es) | Co-cristal constituido por agomelatina y un acido organico que presenta un estado solido a temperatura ambiente; procedimientos de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos del sistema melatoninergico tales como estres, trastornos del sueño y trastornos de ansiedad generalizada, entre otros. | |
| CN104968330A (zh) | 用于治疗剧痛的组合物及方法 | |
| UY25513A1 (es) | Composiciones sólidas que contienen gabapentina y proceso para su preparación | |
| RU2020106285A (ru) | Лечение травматического повреждения головного мозга | |
| CN101868231A (zh) | Ω-3-脂肪酸的新用途 | |
| JP2010522146A5 (cg-RX-API-DMAC10.html) | ||
| WO2007054348A1 (de) | Neue arzneimittel | |
| JP2008508208A (ja) | 炎症性疾患の治療におけるｒｘｒアンタゴニスト | |
| JP2013536209A5 (cg-RX-API-DMAC10.html) | ||
| CN117653656A (zh) | 一种双向调节焦虑抑郁症状的药物组合物及其制备方法和其应用 |